Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 15/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | BMX | P51813 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975638 | 0.86 | FGFR4 (0.75) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16071531 | 0.85 | FGFR4 (0.74) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL16071406 | 0.84 | FGFR4 (0.72) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL6620598 | 0.83 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL20733979 | 0.81 | FGFR4 (0.68) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL15413275 | 0.81 | FGFR4 (0.68) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL28734479 | 0.80 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL28734461 | 0.79 | FGFR4 (0.65) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL1521723 | 0.79 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL20734018 | 0.79 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2022-10-20 | — | — | US | disclosed |
| CN-109384790-B | Fibroblast growth factor receptor inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3943087-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Celgene CAR LLC (BM) | 2022-01-26 | — | — | EP | disclosed |
| CN-109627239-B | Inhibitors of fibroblast growth factor receptors | 缆图药品公司 | 2021-10-12 | — | — | CN | disclosed |
| EP-2968337-B1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-07-21 | — | — | EP | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2020-09-15 | — | — | US | disclosed |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | CELGENE CAR LLC (BM) | 2020-04-14 | — | — | US | disclosed |
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-07-18 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218220-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | PRKACA, PRKDC, AURKC | FGFR4 1590/4885FGFR1 1733/4885FGFR2 879/4885 |
| US-20220332687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885FGFR1 3322/4885FGFR2 1531/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
| US-10774052-B2 | Heteroaryl compounds and uses thereof | ABCG2, CYP3A43, CYP3A5 | FGFR4 2623/4885FGFR1 3322/4885FGFR2 1531/4885 |
| US-10618902-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of protein kinases | PDXK, DCK, DTYMK | FGFR4 1220/4885FGFR1 1156/4885FGFR2 1158/4885 |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885FGFR1 1/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.